The trial for effect of RFX on hepatic encepalopathy

The trial for effect of RFX on hepatic encepalopathy - The study of the effect of RFX

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029127

Enrollment

100

Registered

2017-09-13

Start date

2017-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic encephalopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)>20 years old 2)The patients obtained the consent 3)>4 weeks of suvival periods 4)AST and ALT > 6 times from the facilities standards

Exclusion criteria

Exclusion criteria: 1)The impossible of oral intake 2)The pharmacokinetics in changed for patient's condition 3)The necessary medicine change the pharmacokinetics of rifaximin 4)The pregnancy and lactaing 5)The allergy of rifaximin 6)The outcome evaluation is difficult for patient's condition 7)The execution plan of achievement is difficult

Design outcomes

Primary

Measure	Time frame
1.Improvment of HE 2.Improvment of the intestinal becterial flora	—

Countries

Japan

Contacts

Public ContactHiroaki Hiroaki Takaya

Nara medical unversity 3rd department of interanal medicine

htky@naramed-u.ac.jp0744-22-3051

Outcome results